Aclaris Therapeutics (ACRS) Non-Current Deferred Tax Liability (2017 - 2023)

Aclaris Therapeutics' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $367000.0 for Q3 2023.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $367000.0 in Q3 2023; TTM through Sep 2023 was $367000.0, a 0.0% change from a year earlier, with the FY2022 full-year figure at $367000.0, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability was little changed at $367000.0 in Q3 2023 per ACRS's latest filing, from $367000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $549000.0 in Q1 2019 and bottomed at $367000.0 in Q4 2020.
• The 5-year median for Non-Current Deferred Tax Liability is $367000.0 (2020), against an average of $434052.6.
• Across the five-year window, Non-Current Deferred Tax Liability changed 0.0% in 2019 and slumped 33.15% in 2020, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $549000.0 in 2019, then slumped by 33.15% to $367000.0 in 2020, then changed by 0.0% to $367000.0 in 2021, then changed by 0.0% to $367000.0 in 2022, then changed by 0.0% to $367000.0 in 2023.
• Per Business Quant, the three latest ACRS Non-Current Deferred Tax Liability figures stand at $367000.0 (Q3 2023), $367000.0 (Q2 2023), and $367000.0 (Q1 2023).